Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 24, 1994 - Issue 4
Submit an article Journal homepage
51
Views
42
CrossRef citations to date
0
Altmetric
Research Article

Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects

C. W. Filer Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
G. D. Allen Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
T. A. Brown Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
S. E. Fowles Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
F. J. Hollis Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
E. E. Mort Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
,
W. T. Prince Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
&
J. V. Ramji Drug Metabolism and Pharmacokinetics Department, Smith Kline Beecham Pharmaceuticals, The Frythe, Welwyn, Herts, AL6 9AR, UK
 show all
Pages 357-368 | Received 20 Aug 1993, Published online: 22 Sep 2008

References

  • Allen G. D. Modfit; a pharmacokinetic program. Biopharmaceutics and Drug Disposition 1990; 11: 477–498
  • Boyd M. R. Update on famciclovir. Antiviral Chemotherapy: New Directions for Clinical Application and Research, J. Mills, L. Corey. PTR Prentice Hall, NJ 1993; Vol. 3: 29–37
  • Boyd M. R., Bacon T. H., Button D. Antiherpes virus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in animals. Antimicrobial Agents and Chemotherapy 1988a; 32: 358–363
  • Boyd M. R., Bacon T. H., Sutton D., Cole M. Antiherpes virus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrobial Agents and Chemotherapy 1987; 31: 1238–1242
  • Boyd M. R., Boon R., Fowles S. E., Pagano K., Sutton D., Vere Hodge R. A., Zussman B. D. Some biological properties of BRL 42810, a well absorbed prodrug of the antiherpesvirus agent BRL 39123. Antiviral Research 1988b; 9: 146
  • Clarke S. E., Harrell A. W., Chenery R. J. The role of aldehyde oxidase in the biotransformation of famciclovir to percilovir as determined by a human in vitro system. Proceedings of Fifth European ISSX Meeting, Tours,France,1993; 6: 61
  • De Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. Journal of Antimicrobial Chemotherapy 1983; 12(Suppl. B)29–37
  • De Miranda P., Good S. S. Species differences in the metabolism and disposition of antiviral nucleoside analogues. 1. Acyclovir. Antiviral Chemistry and Chemotherapy 1992; 3: 1–8
  • De Miranda P., Krasny H. C., Page D. A., Elion G. B. The disposition of acyclovir in different species. Journal of Pharmacology and Experimental Therapy 1981; 219: 309–315
  • Fowles S. E., Pierce D. M., Prince W. T., Staniforth D. The tolerance to and Pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. European Journal of Clinical Pharmacology 1992; 43: 513–516
  • Harrell A. W., Wheeler S. M., Pennick M., Clarke S. E., Chenery R. J. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6β-hydroxylation of testosterone in human liver microsomes. Drug Metabolism and Disposition 1993; 21: 18–23
  • Jacobson M. A., De Miranda P., Cederberg D. M., Burnett T., Cobb E., Brodie H. R., Mills J. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrobial Agents and Chemotherapy 1987; 31: 1251–1254
  • Pratt S. K., Fairless A. J., Pue M. A., Fowles S. E., Laroche J., Georgiou P., Prince W. T. Linearity of the pharmacokinetics of penciclovir following oral administration of famciclovir over the therapeutic dose range 125 to 750 mg. British Journal of Clinical Pharmacology 1993; 34: 80P–81P
  • Pue M. A., Benet L. Z. Pharmacokinetics of famciclovir in man. Antiviral Chemistry and Chemotherapy 1994; 4(Supplement 1)47–55
  • Vere Hodge R. A., Sutton D., Boyd M. R., Harnden M. R., Jarvest R. L. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpes virus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; penciclovir]. Antimicrobial Agents and Chemotherapy 1989; 33: 1765–1773
  • Winton C. F., Fowles S. E., Pierce D. M., Vere Hodge R. A. Gradient high-performance liquid chromatographic method for the analysis of the pro-drug famciclovir and its metabolites, including the active anti-viral agent penciclovir, in plasma and urine. Analytical Proceedings 1990; 27: 181–182

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.